The company expects to save an additional $1.2 billion from automation, AI and other digital tools.

Pfizer said on Tuesday it would generate $1.7 billion more in savings from cost cuts to its manufacturing and research ...

Pfizer maintained its 2025 guidance but noted it does not include any impact of tariffs or trade policy, “which we are unable ...

It comes as drugmakers brace for Trump’s levies on pharmaceuticals imported into the U.S. – his administration’s bid to boost ...

Pfizer expanded its cost-cutting plans and posted first-quarter profit above estimates, despite a decline in sales driven by ...

Big pharmaceutical companies as well as smaller biotechs have been hoping to score a win in one of today's highest-growth ...

Pfizer is facing some revenue pressures due to some higher Medicare discounts. Read more to see why I upgrade PFE stock from ...

Albert Bourla said Pfizer is being "frugal" with investments because of the uncertainty surrounding tariffs.

Goldman Sachs keeps Neutral on Pfizer, citing unclear product growth plans and focus on M&A amid changing market valuations ...

Despite a 6% revenue drop, Pfizer Inc (PFE) focuses on R&D advancements, cost savings, and dividend growth to drive future ...

The company disclosed revenue of $13.7 billion and adjusted earnings of $0.92 per share, compared to consensus estimates of ...

The market for obesity drugs presents one of the most lucrative targets for biopharmaceutical companies. Eli Lilly and Novo Nordisk are already raking in billions of dollars in sales with their weight ...